Drugs / antithymocyte globulin (horse)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01049854 | Sep 2011 → Nov 2017 | beta thalassemia, bone marrow failure syndrome, histiocytosis, immunodeficiency disease +4 | New York Medical College | Completed | No outcome recorded |
| Phase 2 | NCT00260689 | Nov 2005 → May 2016 | neutropenia, pancytopenia, thrombocytopenia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00186810 Background | Dec 1992 → Feb 2006 | sickle cell disease | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Thymocyte Globulin (horse) | “Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1.” NCT01049854 ↗2“Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan.” NCT00186810 ↗ |
| Known as | h-ATG | “h-ATG (Anti-thymocyte globulin (horse))” NCT00260689 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Anti-thymocyte globulin (horse)” NCT00260689 ↗ |